Effects of Acute Sleep Deprivation on Individuals With Different APOE Genotypes
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorYuhui Qiu
About this trial
This study aims to investigate the effects of 24-hour acute sleep deprivation on plasma Alzheimer's disease biomarkers and multi-omics in individuals with different APOE genotypes, to elucidate the potential role of acute sleep deprivation in AD risk.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 18-40 years, gender not limited
Healthy (with no clinically significant abnormal findings in the physical examination report or self-reporting as healthy) and not on medications
Cognitively normal (Mini-Mental State Examination (MMSE) score > 28)
Sleep duration of 7-9 hours per night, good sleep quality (Pittsburgh Sleep Quality Index (PSQI) ≤ 5 points)
Disqualifiers
Presence of day-night sleep reversal
Shift work within the past 6 months
Travel across time zones or experience of jet lag within the past three weeks
Current smoking or nicotine use; alcohol consumption exceeding five standard units per week (one standard alcohol unit is defined as 10 mL [or 8 g] of pure alcohol)
Trial design
Design model
Parallel
Treatments tested in this trial
Sleep Deprivation
BehavioralSleep deprivation for up to 24 hours with no naps or other sleep periods
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Sleep DeprivationExperimental treatment 1 intervention
Group B: ControlNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Plasma Aβ42 levels
Time frame
1 day after randomizationSecondary outcomes
1
Plasma Aβ40 levels
Time frame
1 day after randomization2
Plasma t-tau levels
Time frame
1 day after randomization3
Plasma p-tau181 levels
Time frame
1 day after randomization4
Plasma p-tau217 levels
Time frame
1 day after randomizationOther outcomes
1
PET/MRI
Assessed using Positron Emission Tomography/Magnetic Resonance Imaging(PET/MRI)
Time frame
1 day after randomization2
Proteomics
The plasma proteomics will be determined by Liquid Chromatography - MassSpectrometry
Time frame
1 day after randomization3
Metabolomics
The plasma metabolomics will be determined by Liquid Chromatography - MassSpectrometry
Time frame
1 day after randomizationSponsors and contacts
Click on the lead sponsor to view all of their trials.
Yuhui Qiu
Lead sponsor
Guangdong Provincial Hospital of Traditional Chinese Medicine
Sponsor institution
Source ClinicalTrials.gov